Société
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Evora develops EVOGEX, a thermoresponsibe gel loaded with exosomes. EVOGEX's lead indication are complex digestive fistulas, which appear in Crohn's Disease patients and following digestive surgery complications.
Paris, Île-de-France, France
Envoyer un message
Français
Français
Evora Biosciences is a biotechnology startup which develops exosomal therapies.
Exosomal therapies are considered to be the next generation of regenerative cell therapies. Indeed, stem cell-derived exosomes exhibit similar therapeutic properties as stem cells, while alleviating several major pain points of cell therapy, mostly logistics- (production, storage, transport) and cost-related.
Evora's lead product, EVOGEX, targets the 50K+ patients treated every year in the US and...
Evora Biosciences is a biotechnology startup which develops exosomal therapies.
Exosomal therapies are considered to be the next generation of regenerative cell therapies. Indeed, stem cell-derived exosomes exhibit similar therapeutic properties as stem cells, while alleviating several major pain points of cell therapy, mostly logistics- (production, storage, transport) and cost-related.
Evora's lead product, EVOGEX, targets the 50K+ patients treated every year in the US and Europe for complex digestive fistulas. EVOGEX is supported by exciting invivo results, and our goal is to start clinical trials in 2023.
1
Followers